PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

The Colorado Center for Personalized Medicine highlighted as a leader in precision medicine in research and clinical care

CCPM hits major milestone of returning genetic results to over 30,000 patients and leads in global research efforts

2024-01-04
(Press-News.org) A new peer-reviewed study in the American Journal of Human Genetics highlights the work of the biobank at the Colorado Center for Personalized Medicine (CCPM), a world-class site for precision medicine in research and clinical care created in partnership with the University of Colorado Anschutz Medical Campus and UCHealth.

The paper focuses on CCPM’s research and personalized medical care.  

“We’re one of the only institutions in the world that has accomplished the dual-purpose of using genetic information to accelerate scientific discovery in research while providing actionable clinical results to patients that can lead to preventative measures for diseases or inform on potential medication reactions,” said the paper’s senior author Chris Gignoux, PhD, MS, professor of Biomedical Informatics at CU Anschutz and the Director of Research for CCPM.  

The center recently hit a major milestone of returning clinical genetic results to over 30,000 patients. This makes it a leader in providing personalized patient care, care tailored to someone’s genetic makeup. The center has over 235,000 participants enrolled in their biobank with active enrollment available to any patients in the UCHealth system. The collaboration between CU Anschutz Medical Campus and UCHealth through CCPM represents a true genomic learning health system, leading in local and global efforts to advance genomic medicine.  

“CU Anschutz’s strong partnership with UCHealth positions us to bring genetics to the point of care, delivering personalized medicine at a large scale. This enables us to translate research insights directly into clinical applications, all on one campus,” said Casey Greene, PhD, Interim Director of CCPM and inaugural Chair of the Department of Biomedical Informatics at CU Anschutz.  

The center has been able to notify and provide recommendations on care for patients who have variants in genes that put them at increased hereditary risk for breast cancer, ovarian cancer risk, or cardiac-related conditions, to name a few.

They are also studying pharmacogenomics, or how genetic variations influence an individual's response to medications, and providing results to patients and doctors to guide drug selection and dosing. This is especially important in oncology, psychiatry, cardiology, and other fields where individual responses to medications can vary widely. 

“By releasing pharmacogenomic results into the medical record even before a biobank participant may need one of the affected drugs means that if and when they do need treatment their healthcare providers can identify the best medication or dose for them immediately,” said co-first author Laura Wiley, PhD, MS, associate professor of Biomedical Informatics and Chief Data Scientist of Health Data Compass at CU Anschutz, highlighting the work of a team led by Christina Aquilante, PharmD, CCPM’s Director of Pharmacogenomics and a professor of Pharmaceutical Sciences at CU Anschutz.

At the same time, the biobank at CCPM is available to the University of Colorado (CU) experts for basic, translational and clinical research across a range of both acute and chronic conditions. CU faculty are conducting studies on the architecture of common cardiovascular, immune, metabolic and anthropometric traits, where genetics may play a significant role in developing disease.

Over the next few years, CCPM hopes to expand their clinical and genomic data by increasing the number of participants to the hundreds of thousands. Through CCPM initiated efforts and collaborations with national and international partners facilitated by CCPM resources, the center hopes to discover novel insights to inform targeted, personalized strategies to continue to improve health outcomes.  

About the University of Colorado Anschutz Medical Campus

The University of Colorado Anschutz Medical Campus is a world-class medical destination at the forefront of transformative science, medicine, education and patient care. The campus encompasses the University of Colorado health professional schools, more than 60 centers and institutes, and two nationally ranked independent hospitals - UCHealth University of Colorado Hospital and Children's Hospital Colorado - that treat more than two million adult and pediatric patients each year. Innovative, interconnected and highly collaborative, the University of Colorado Anschutz Medical Campus delivers life-changing treatments, patient care and professional training and conducts world-renowned research fueled by over $704 million in research grants. For more information, visit www.cuanschutz.edu.

About UCHealth 

UCHealth is an innovative, nonprofit health system that delivers the highest quality medical care with an excellent patient experience. UCHealth includes 33,000 employees, 14 acute-care hospitals and hundreds of physicians across Colorado, southern Wyoming and western Nebraska. With University of Colorado Hospital on the CU Anschutz Medical Campus as its academic anchor and the only adult academic medical center in the region, UCHealth is dedicated to providing unmatched patient care in the Rocky Mountain West. Offering more than 150 clinic locations, UCHealth provides extensive community benefits and pushes the boundaries of medicine through advanced treatments and clinical trials, improving health through innovation. 

END


ELSE PRESS RELEASES FROM THIS DATE:

Treating tuberculosis when antibiotics no longer work

2024-01-04
In cooperation with research partners in Germany and France, the infectious disease specialist Dr Jan Rybniker and his team at University Hospital Cologne and the University of Cologne’s Faculty of Medicine have identified new, antibiotic molecules that target Mycobacterium tuberculosis and make it less pathogenic for humans. In addition, some of the discovered substances may allow for a renewed treatment of tuberculosis with available medications – including strains of the bacterium that have already developed drug resistance. The research has been published in the article ‘Discovery of dual-active ethionamide boosters ...

Supercharging CAR-T cells for cancer treatment

2024-01-04
At EPFL's School of Engineering, Professor Li Tang's Laboratory of Biomaterials for Immunoengineering has made significant strides in cancer treatment research. In laboratory settings, this innovative CAR-T therapy has consistently eradicated cancerous tumors in mouse models. Separately, in on-going clinical trials, eleven patients seemed to achieve complete remission using this treatment, marking a success rate of 100% to date. Notably, evidence from the lab study, published in Nature Biotechnology, suggests the therapy's long-term effectiveness, and indicates that its fabrication may be both quicker and more cost-effective ...

Minimizing immunotherapy’s potentially harmful side effects

Minimizing immunotherapy’s potentially harmful side effects
2024-01-04
MIAMI, FLORIDA (EMBARGOED UNTIL JAN. 4, 2024, at 10 AM EST) – Recent advances in treating multiple myeloma, the second most common blood cancer, and other blood malignancies are providing improved outcomes – and hope – to patients worldwide. But treatment breakthroughs such as the immunotherapy drug teclistamab can lead to potentially lethal side effects, including cytokine release syndrome (CRS) and immune cell-associated neurotoxicity syndrome (ICANS). These potential side effects have necessitated giving immunotherapy drugs in the hospital setting, where patients remain for five to seven days and receive other drugs ...

Study finds paxlovid treatment does not reduce risk of long COVID

2024-01-04
A team of researchers from UC San Francisco has found that Paxlovid (Nirmatrelvir-ritonavir) did not reduce the risk of developing long COVID for vaccinated, non-hospitalized individuals during their first COVID-19 infection. They also found a higher proportion of individuals with acute symptoms rebound and test-positivity than previously reported. The study appears Jan. 4, 2024, in the Journal of Medical Virology. Paxlovid treatment for acute COVID-19 has been shown to be effective for high-risk unvaccinated individuals. But the effect of the treatment on long COVID risk, including whether it protects vaccinated people from getting long COVID, has been less clear. The ...

Menarini Group and Insilico Medicine enter global exclusive license agreement for novel KAT6 inhibitor for potential breast cancer treatment and other oncology indications

Menarini Group and Insilico Medicine enter global exclusive license agreement for novel KAT6 inhibitor for potential breast cancer treatment and other oncology indications
2024-01-04
● KAT6 is an emerging target in hormone sensitive breast tumors and other cancers. Overexpression of KAT6A/B correlates with poor clinical outcomes in patients with ER+/HER2- breast cancer – the most common subtype. ● The molecule has demonstrated strong preclinical activity. Insilico Medicine presented data on the novel molecule at the San Antonio Breast Cancer Symposium in early December. ● This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties. FLORENCE, Italy and NEW YORK: The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, ...

New population risk prediction model for likelihood of ICU admission and survival

2024-01-04
INDIANAPOLIS – A significant obstacle to improving care and outcomes for intensive care unit (ICU) patients is the unexpected nature of becoming seriously ill. Which groups of patients are likely to become severely ill and will they survive their ICU stay? In a first step in creating infrastructure for further studies to identify and follow cohorts of patients who may become critically ill, researchers including Sikandar Khan, D.O, M.S., of Regenstrief Institute and Indiana University School of Medicine, have developed and conducted ...

Chung-Ang University study reveals a higher market valuation of cash holdings of firms adopting electronic voting

Chung-Ang University study reveals a higher market valuation of cash holdings of firms adopting electronic voting
2024-01-04
Firms worldwide are increasingly adopting electronic voting, enabling shareholders to cast their votes online, instead of attending shareholder meetings in-person. Shareholders can enjoy superior accessibility to the meetings with electronic voting, compared to those with traditional and in-person setups. Despite the emerging popularity of electronic voting in recent years, however, there is limited evidence of its impact on governance. To address this gap in research, Associate Professor Wonsuk Ha from the School of Business Administration, Chung-Ang University, along ...

Women undergoing fertility treatment who are stressed may have heart health issues during pregnancy

2024-01-04
WASHINGTON—A new Journal of the Endocrine Society study among women attending a fertility center found that those with more stress before pregnancy had higher blood sugar levels during pregnancy, which is a sign of weaker cardiovascular health. People’s stress levels have continued to rise over the years, particularly in the last few years due to the COVID-19 pandemic, putting them at risk for serious health issues such as heart disease. Research shows women may experience more stress than men, especially those going through infertility. Maintaining a healthy pregnancy ...

Study finds preconception stress may affect health of women undergoing fertility treatment

2024-01-04
Stress during pregnancy is known to influence health outcomes, but a new study from Mass General Brigham researchers suggests that stress levels before pregnancy are also important to evaluate. Investigators at Massachusetts General Hospital and Brigham and Women’s Hospital analyzed the link between self-reported stress immediately before conception among women seeking fertility care and blood glucose levels, a marker of heart health. The team found that maternal stress during preconception ...

AI-driven study redefines right heart health assessment with novel predictive model

AI-driven study redefines right heart health assessment with novel predictive model
2024-01-04
New York, NY [January 4, 2023]—In a milestone study, researchers from the Icahn School of Medicine at Mount Sinai have harnessed the power of artificial intelligence (AI) to enhance the assessment of the heart’s right ventricle, which sends blood to the lungs.  Conducted by a team using AI-enabled electrocardiogram (AI-ECG) analysis, the research demonstrates that electrocardiograms can effectively predict right-side heart issues, offering a simpler alternative to complex imaging technologies and potentially enhancing patient outcomes. The findings were described in the December 29 online ...

LAST 30 PRESS RELEASES:

Impact of pollutants on pollinators, and how neural circuits adapt to temperature changes

Researchers seek to improve advanced pain management using AI for drug discovery

‘Neutron Nexus’ brings universities, ORNL together to advance science

Early release from NEJM Evidence

UMass Amherst astronomer leads science team helping to develop billion-dollar NASA satellite mission concept

Cultivating global engagement in bioengineering education to train students skills in biomedical device design and innovation

Life on Earth was more diverse than classical theory suggests 800 million years ago, a Brazilian study shows

International clean energy initiative launches global biomass resource assessment

How much do avoidable deaths impact the economy?

Federal government may be paying twice for care of veterans enrolled in Medicare Advantage plans

New therapeutic target for cardiac arrhythmias emerges

UC Irvine researchers are first to reveal role of ophthalmic acid in motor function control

Moffitt study unveils the role of gamma-delta T cells in cancer immunology

Drier winter habitat impacts songbirds’ ability to survive migration

Donors enable 445 TPDA awards to Neuroscience 2024

Gut bacteria engineered to act as tumor GPS for immunotherapies

Are auditory magic tricks possible for a blind audience?

Research points to potential new treatment for aggressive prostate cancer subtype

Studies examine growing US mental health safety net

Social risk factor domains and preventive care services in US adults

Online medication abortion direct-to-patient fulfillment before and after the Dobbs v Jackson decision

Black, Hispanic, and American Indian adolescents likelier than white adolescents to be tested for drugs, alcohol at pediatric trauma centers

Pterosaurs needed feet on the ground to become giants

Scientists uncover auditory “sixth sense” in geckos

Almost half of persons who inject drugs (PWID) with endocarditis will die within five years; women are disproportionately affected

Experimental blood test improves early detection of pancreatic cancer

Groundbreaking wastewater treatment research led by Oxford Brookes targets global challenge of toxic ‘forever chemicals’

Jefferson Health awarded $2.4 million in PCORI funding

Cilta-cel found highly effective in first real-world study

Unleashing the power of generative AI on smart collaborative innovation network platform to empower research and technology innovation

[Press-News.org] The Colorado Center for Personalized Medicine highlighted as a leader in precision medicine in research and clinical care
CCPM hits major milestone of returning genetic results to over 30,000 patients and leads in global research efforts